Posts Tagged ‘biotech’

BREXIT AND TAX: WHAT’S IN STORE FOR BIOTECHS?

Union-Jack-flag-with-Brexit-word

THERE IS no doubt that biotech fundraising rounds are getting bigger, companies are getting bigger and, as tax advisors, we are being faced with previously unheard of issues. Take profits – these could result in corporation tax liabilities, groups so large or profitable that they cannot claim SME R&D tax credits or future milestone income…

Read More

UK: A GREAT OPTION FOR US R&D

Triangular sign saying explore on a wooden background

WHY THE UK ROCKS FOR RESEARCH During a January visit to San Francisco to coincide with the JP Morgan conference, it was encouraging to hear from one US biotech company CFO how he considered the UK an attractive place to base his company’s research activities – above and beyond any other. Among the reasons why…

Read More

Autumn 2017 post-budget tax briefing

Union-Jack-flag-in London-Autumn-2017-budget-for-biotech-companies

You are invited… to the essential Autumn 2017 post-budget tax briefing for biotech and tech companies Key points distilled, digested and presented by the tax experts at Confluence Tax – we’ve done the hard work for you! We would be delighted if you could join us on November 23, 2017 in the Cambridge Building, Babraham…

Read More

Consulting on HMRC digital improvements project

woman-virtual-reality-HMRC-robot

Confluence Tax has been invited to take part in the HMRC research project into digital improvements to its SEIS, EIS and venture capital trust schemes – a great opportunity for us to have our say on the things that bug both us and our biotech and tech clients about the tax system! This stage of the project…

Read More

Life Sciences Structured M&A: seminar Confluence Tax, Dechert, SRS

ON MAY 3 Confluence Tax will be jointly running a seminar on biotech M&A transactions, taking place in London. Structured deals are a key feature of Life Sciences M&A transactions based on the principle of shared risk. These involve significant contingent consideration payable to selling shareholders based on clinical, regulatory and/or sales based milestones. How you negotiate…

Read More